List of Excipients in Branded Drug IPOL

IPOL Excipient Strategy and Commercial Opportunities in Inactivated Polio Vaccine Formulation

Last updated: August 7, 2026

IPOL is Sanofi Pasteur’s inactivated poliovirus vaccine (IPV), supplied as a sterile injectable suspension for intramuscular or subcutaneous administration. Its excipient strategy is based on a conventional vaccine formulation using residual process materials, antimicrobial protection, surfactant stabilization, and buffered aqueous delivery. The strongest commercial opportunities are not likely to come from replacing the antigen itself. They are more likely to arise from preservative reduction, improved thermostability, prefilled delivery systems, combination-vaccine compatibility, and manufacturing processes that reduce residual impurities.

What is IPOL and how is it regulated?

IPOL is a trivalent IPV containing inactivated poliovirus types 1, 2, and 3. The vaccine is produced using poliovirus propagated in Vero cells and inactivated before formulation. The U.S. product is licensed as a biologic under a Biologics License Application rather than as a conventional small-molecule drug application (U.S. Food and Drug Administration [FDA], 2024a).

Attribute	IPOL
Product type	Inactivated poliovirus vaccine
Antigens	Poliovirus types 1, 2, and 3
Manufacturer	Sanofi Pasteur
U.S. regulatory pathway	Biologics License Application
Administration	Intramuscular or subcutaneous injection
Dosage form	Sterile injectable suspension
U.S. approval history	Licensed in 1990
Primary use	Active immunization against poliomyelitis
Orange Book status	Not generally listed as a conventional Orange Book drug
Reference-product exclusivity	No meaningful remaining U.S. biologic exclusivity period for a product licensed in 1990

IPOL is used in pediatric immunization schedules and may be supplied as a standalone vaccine or selected over combination products where a separate IPV component is clinically or operationally preferred (Centers for Disease Control and Prevention [CDC], 2024).

What excipients are used in the IPOL formulation?

IPOL’s public prescribing information identifies 2-phenoxyethanol, formaldehyde, and polysorbate 80 among formulation or residual process constituents. The product also contains residual antibiotics associated with manufacturing, including neomycin, streptomycin, and polymyxin B. Sodium chloride and water for injection support the final injectable formulation (Sanofi Pasteur, 2024).

The commercial significance of these ingredients differs:

Component	Functional or process role	Commercial relevance
2-Phenoxyethanol	Antimicrobial preservative	Potential target for preservative-free or lower-preservative presentations
Formaldehyde	Viral inactivation process reagent	Residual impurity control and analytical-method opportunity
Polysorbate 80	Surfactant and protein-stabilizing excipient	Potential oxidation, aggregation, and container-interaction concerns
Sodium chloride	Isotonicity adjustment	Low differentiation value
Residual antibiotics	Manufacturing residues	Allergy labeling, process-control, and regulatory-risk considerations
Water for injection	Vehicle	Standard injectable component
Vero-cell process residues	Manufacturing-derived impurities	Opportunity for improved purification and sensitive analytics

Public labeling should be treated as the authoritative source for the current commercial formulation. Vaccine formulations can change through approved manufacturing supplements, and the public label may not disclose every process aid or quantitative concentration.

What excipient patents protect IPOL?

No reliable conclusion can be made that a currently enforceable patent specifically protects the commercial IPOL excipient composition without a live, claim-level patent search across U.S., European, and international family members.

IPOL was licensed in 1990, so any original formulation patents would generally be expected to have expired under ordinary patent-term rules unless a later patent family covered a redesigned formulation, manufacturing process, container, or use. The commercially relevant patent categories are therefore likely to be later-generation claims rather than the original product composition.

Potential patent categories

1. Stabilized IPV formulations
   Claims may cover defined ratios of surfactant, buffer, salts, amino acids, sugars, or polyols that preserve D-antigen potency during storage.

2. Low-temperature or thermostable formulations
   Claims may cover formulations that maintain immunogenicity after exposure to elevated temperatures or repeated temperature excursions.

3. Combination-vaccine compatibility
   A patent may cover the physical or immunological compatibility of IPV with diphtheria, tetanus, pertussis, Haemophilus influenzae type b, hepatitis B, or other vaccine antigens.

4. Preservative-reduced products
   Claims may cover single-dose presentations with reduced 2-phenoxyethanol or alternative antimicrobial systems.

5. Vero-cell purification and impurity removal
   Process claims may target removal of host-cell DNA, host-cell proteins, residual antibiotics, or inactivating agents.

6. Container-closure systems
   Prefilled syringes, low-adsorption polymer components, extractables-resistant materials, and dose-delivery systems may support separate patent protection.

The strongest enforceable position would normally require claims that combine a defined excipient composition with measurable stability or potency results. Broad claims directed only to routine use of sodium chloride, water, formaldehyde, or polysorbate 80 would face significant validity and prior-art pressure.

How strong is the IPOL excipient estate?

The likely strength of an IPOL-related excipient estate depends more on later formulation and process patents than on the legacy vaccine composition.

Patent area	Likely strength	Reason
Basic aqueous IPV formulation	Low	Conventional excipients and extensive vaccine prior art
Defined stabilizer combinations	Moderate	Strength depends on unexpected potency or stability data
Thermostability	Moderate to high	Commercial value and measurable performance can support narrower claims
Preservative-free presentation	Moderate	Stronger when linked to single-dose packaging and validated sterility
Vero-cell purification	Moderate to high	Process complexity may create meaningful manufacturing barriers
Combination-vaccine compatibility	Moderate	Clinical and formulation data can be difficult to design around
Prefilled syringe or device	Moderate	Claims may be vulnerable to alternative device configurations
Manufacturing analytics	Low to moderate	Proprietary methods may provide know-how more often than durable patents

A formulation patent is more defensible when it claims a narrow excipient range, a specific antigen concentration, a defined manufacturing sequence, and a demonstrated technical effect. Patent applications that merely substitute one conventional buffer or surfactant for another are more exposed to obviousness challenges.

What are the commercial opportunities in IPOL excipients?

Can a preservative-free IPOL presentation create value?

Yes. A single-dose, preservative-free presentation could address concerns about preservative exposure, simplify pediatric administration, and align with procurement preferences in markets that favor single-use vaccine formats. The commercial value would depend on whether the change improves purchasing access, reduces adverse-event concerns, or enables a premium prefilled syringe.

The regulatory burden would remain substantial. The sponsor would need to demonstrate sterility assurance, container-closure integrity, stability, extractables and leachables control, and comparability of antigen potency.

Can thermostable IPV formulations expand access?

Thermostability is the most commercially important excipient opportunity. IPV distribution depends on cold-chain storage, typically within a refrigerated range. A formulation that tolerates temporary temperature excursions could reduce wastage and improve deployment in lower-resource settings.

Potential technologies include:

• Sugar or polyol stabilizers.
• Amino-acid-based stabilization.
• Surfactant optimization.
• Lyophilized or partially dried presentations.
• Improved vial or syringe systems.
• Excipient combinations that reduce antigen adsorption or aggregation.

A thermostable product would need potency data after defined heat exposures, real-time stability data, accelerated stability data, and evidence that the altered formulation maintains immunogenicity.

Are prefilled syringes a meaningful opportunity?

Prefilled syringes could improve dose accuracy, reduce preparation steps, and lower contamination risk. They also create a packaging and device patent opportunity separate from the excipient composition.

Commercial barriers include:

• Higher component cost.
• Compatibility between polysorbate 80 and syringe materials.
• Silicone-oil interactions.
• Extractables and leachables.
• Increased shipping volume.
• Need for device-specific human-factors and container-closure validation.

The best opportunity may be a low-volume, low-waste presentation for public-health procurement rather than a premium retail product.

Can excipient changes support combination vaccines?

IPV is already present in combination vaccines such as Pediarix, Pentacel, Kinrix, and Quadracel. A standalone IPOL formulation must therefore compete partly with combination products that reduce the number of injections.

Excipient innovation could support:

• Improved compatibility with other antigens.
• Longer in-use stability after reconstitution or opening.
• Reduced adsorption between antigens and container surfaces.
• Lower overall injection volume.
• A formulation suitable for broader combination products.

Combination-vaccine formulation patents may be more commercially valuable than standalone IPV excipient patents because they can protect a broader product architecture and create switching costs for competitors.

What FDA requirements apply to IPOL formulation changes?

A material excipient change would normally require a supplement to the BLA rather than an abbreviated generic application. The sponsor would need to establish that the modified product remains comparable in quality, safety, and effectiveness.

Key CMC elements include:

• Identity and potency of poliovirus types 1, 2, and 3.
• D-antigen content.
• Residual formaldehyde.
• Residual antibiotics.
• Host-cell DNA and protein.
• Sterility and endotoxin.
• Particulate matter.
• pH and osmolality.
• Container-closure integrity.
• Real-time and accelerated stability.
• Antigen adsorption and aggregation.
• Comparability before and after the change.

A change that affects antigen structure, potency, or immunogenicity may require additional nonclinical or clinical evidence. FDA’s vaccine guidance emphasizes a risk-based approach, but excipient modifications cannot be assumed to qualify for a minor manufacturing supplement merely because the active antigen remains unchanged (FDA, 2024b).

When does IPOL lose exclusivity and face generic entry?

IPOL has no practical remaining originator exclusivity period based on its 1990 U.S. licensure. The principal barrier to competition is regulatory and manufacturing complexity, not basic market exclusivity.

A conventional “generic” pathway is unlikely to mirror the ANDA model used for small molecules. A competing IPV product would likely require its own biologics license or another applicable biologics pathway. The sponsor would need to establish manufacturing consistency, viral inactivation, impurity control, potency, safety, and immunogenicity.

Generic and biosimilar risk

IPV is a biologic vaccine, but the competitive risk is different from that of monoclonal antibodies:

• A biosimilar-style pathway may be possible in principle but is not the primary commercial framework for most standalone vaccines.
• Manufacturing know-how is difficult to replicate.
• Poliovirus production requires controlled facilities and validated inactivation.
• Vero-cell processes create substantial analytical and impurity-control requirements.
• Public-sector procurement can support competition even without automatic substitution.
• Combination vaccines reduce the addressable market for standalone IPV.

The most credible entrant would likely be an established vaccine manufacturer or public-sector supplier, not a conventional generic-drug company.

Which companies compete with IPOL?

IPOL competes directly with other IPV products and indirectly with combination vaccines.

Product or company	Competitive relationship
Sanofi Pasteur IPOL	Standalone trivalent IPV
GSK, Infanrix hexa and related products	Combination-vaccine competition in markets where available
Sanofi Pasteur Pentacel	IPV-containing combination vaccine
GSK Pediarix	IPV-containing combination vaccine
Sanofi Pasteur Kinrix and Quadracel	IPV-containing booster combinations
Serum Institute of India	Major global vaccine supplier with polio-vaccine manufacturing capacity
Biological E and other regional manufacturers	Potential public-health and tender competition

Product availability varies by country, procurement contract, and national immunization schedule.

What patent litigation and Paragraph IV risks affect IPOL?

There is no standard small-molecule Paragraph IV pathway that creates the same immediate litigation pattern for IPOL as it does for an Orange Book-listed drug. IPOL is a biologic vaccine licensed under the BLA framework, and its core commercial protection is not ordinarily managed through a conventional Orange Book patent listing.

Potential disputes could instead involve:

• BLA approval of a competing IPV.
• Patent claims covering thermostable formulations.
• Vero-cell production methods.
• Viral inactivation conditions.
• Combination-vaccine formulations.
• Prefilled syringe configurations.
• Trade secrets involving purification and analytical controls.

A later entrant may avoid infringement by using a different preservative system, stabilizer, cell substrate, purification train, or container. This makes process and formulation claim drafting central to any competitive strategy.

What licensing opportunities exist around IPOL excipients?

The most attractive licensing targets are technologies that solve a defined manufacturing or distribution problem:

1. Thermostability platforms licensed to vaccine manufacturers.
2. Low-adsorption or low-silicone syringe systems for protein and virus vaccines.
3. Preservative-free antimicrobial control technologies for multidose or single-dose products.
4. Vero-cell impurity-removal methods with validated reductions in residual DNA and proteins.
5. Analytical methods for polysorbate degradation, antigen aggregation, and residual formaldehyde.
6. Lyophilization or controlled-drying systems for IPV or combination vaccines.
7. Cold-chain monitoring and stability-indicating packaging tied to vaccine distribution.

Licensing value rises when the technology is compatible with existing manufacturing equipment and can be introduced through a manageable BLA supplement. A technology requiring a new production platform, new container, and new clinical comparability package will face a longer adoption cycle.

What is the commercial outlook for IPOL excipient innovation?

IPOL’s standalone U.S. market is constrained by combination vaccines and mature pediatric immunization schedules. The broader opportunity is global and procurement-driven. A successful excipient technology must reduce total delivered cost, cold-chain losses, injection burden, or manufacturing complexity.

The highest-value opportunities are:

• Thermostable IPV for emerging-market distribution.
• Single-dose preservative-free prefilled syringes.
• Formulations compatible with next-generation combination vaccines.
• Purification methods that reduce residual process impurities.
• Packaging systems that improve stability without increasing dose cost materially.

The weakest opportunity is a simple substitution of one conventional excipient for another without a measurable improvement in potency, stability, safety, manufacturability, or logistics.

Key Takeaways

• IPOL is a Sanofi Pasteur trivalent inactivated poliovirus vaccine licensed under a BLA.
• Its public formulation includes 2-phenoxyethanol, formaldehyde, polysorbate 80, sodium chloride, water for injection, and residual antibiotics.
• IPOL has no practical remaining original-product exclusivity period based on its 1990 U.S. licensure.
• Conventional Orange Book and Paragraph IV strategies do not define the main competitive pathway.
• Thermostability, preservative reduction, prefilled delivery, and Vero-cell impurity control are the leading excipient-related opportunities.
• The most defensible patents would combine narrow composition ranges with validated potency, stability, or manufacturing advantages.
• Manufacturing capability, BLA requirements, cold-chain economics, and public-sector procurement are more important competitive barriers than legacy formulation patents.

FAQs

Does IPOL contain mercury or thimerosal?

The current U.S. IPOL label does not identify thimerosal as an ingredient. The labeled formulation includes 2-phenoxyethanol as a preservative or antimicrobial component.

Is IPOL a live or inactivated vaccine?

IPOL is an inactivated vaccine. Its poliovirus antigens are chemically inactivated and cannot replicate.

Can IPOL be replaced by a generic injectable?

Replacement would generally require regulatory authorization for a biologic vaccine. A conventional small-molecule ANDA substitution model is not the standard pathway.

Are IPOL’s residual antibiotics commercially important?

Yes. Residual neomycin, streptomycin, and polymyxin B affect labeling, allergy management, process controls, and the commercial value of impurity-reduction technologies.

Would a thermostable IPOL formulation qualify for a new patent?

Potentially, but patentability would depend on novelty, nonobviousness, claim scope, and data showing a measurable technical effect. A routine excipient substitution without unexpected stability or potency results would be vulnerable to prior-art challenges.

References

1. Centers for Disease Control and Prevention. (2024). Child and adolescent immunization schedule by age. https://www.cdc.gov/vaccines/schedules/

2. Sanofi Pasteur. (2024). IPOL: Poliovirus vaccine inactivated prescribing information. U.S. Food and Drug Administration labeling database.

3. U.S. Food and Drug Administration. (2024a). Vaccines licensed for use in the United States. https://www.fda.gov/vaccines-blood-biologics/vaccines

4. U.S. Food and Drug Administration. (2024b). Chemistry, manufacturing, and control information for human vaccine biological products. https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances-controls-manufacturing.